Connor, Clark & Lunn Investment Management (CC&L)’s Arcus Biosciences RCUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.08M Buy
281,681
+78,413
+39% +$1.69M 0.01% 626
2025
Q4
$4.84M Buy
203,268
+117,210
+136% +$2.39M 0.01% 658
2025
Q3
$1.17M Buy
+86,058
New +$895K ﹤0.01% 1012
2025
Q1
Sell
-64,043
Closed -$954K 1570
2024
Q4
$954K Buy
+64,043
New +$1.05M ﹤0.01% 947
2022
Q2
Sell
-212,743
Closed -$6.71M 1177
2022
Q1
$6.71M Sell
212,743
-53,800
-20% -$1.8M 0.03% 279
2021
Q4
$10.8M Sell
266,543
-6,064
-2% -$235K 0.05% 230
2021
Q3
$9.51M Buy
272,607
+3,896
+1% +$121K 0.05% 253
2021
Q2
$7.38M Buy
268,711
+49,586
+23% +$1.42M 0.04% 282
2021
Q1
$6.15M Buy
219,125
+24,586
+13% +$856K 0.03% 316
2020
Q4
$5.05M Buy
194,539
+108,525
+126% +$2.63M 0.03% 336
2020
Q3
$1.47M Buy
+86,014
New +$1.92M 0.01% 539

Other funds holding RCUS